Net Income

A new survey reveals over half of Americans delay healthcare, creating a 'health debt' crisis fueled by cost fears and scheduling conflicts for younger generations.

A new partnership between Always and The Fibroid Foundation aims to break the silence on heavy periods and fibroids, combining product innovation with advocacy.

With book value soaring, Stack Capital offers a rare public window into the massive valuations of private titans like SpaceX and the AI infrastructure boom.

Taiwanese biotech GNTbm's oral drug GNTbm-38, which turns 'cold' tumors 'hot', will begin Phase 1 trials for advanced and refractory cancers.

AI firm YXT.com lands on a top innovation list with tech giants, but can its cutting-edge training solutions navigate a complex market and redefine work?

Starton Therapeutics files patents to combine its continuous low-dose therapy, STAR-LLD, with CAR-T, aiming to enhance cancer-killing power and durability.

Iconic Australian bootmaker R.M.Williams expands its partnership with Bamboo Rose, leveraging AI-powered planning to modernize its global operations.

With FDA Breakthrough status for its MASH drug, a new CEO, and a fortified balance sheet, Altimmune is poised to take on serious liver disease and addiction.

With no approved treatments for the deadly pregnancy complication preeclampsia, one company's novel drug is now advancing to a crucial new clinical trial.

The biotech firm accelerates a key trial but faces a partner loss, widening losses, and a CEO search, putting its promising siRNA pipeline at a crossroads.

With a total of $160M in Series B funding, Atavistik Bio is advancing its selective allosteric inhibitors for rare diseases HHT and MPNs.

With a melanoma drug on track for 2027 and a deep pipeline, Immatics' 2025 net loss is part of a larger strategy to dominate PRAME cancer therapy.

With a new outpatient model, NexCure aims to bring life-saving cancer treatments like CAR-T closer to home, tackling a major healthcare bottleneck.

Ituran announces a $30M dividend after a record year, leveraging a unique Israeli tax law to boost shareholder returns and signaling deep confidence.

Investors eye Moody's CEO Rob Fauber's upcoming speech for insights on AI strategy, M&A forecasts, and navigating an increasingly complex global economy.

Struggling manufacturer Highway Holdings acquires a 51% stake in Germany's Regent-Feinbau, a bold move to enter high-value markets and build resilient supply chains.

With mixed trial results for its obesity drug and rising costs, Skye Bioscience's upcoming 2025 earnings call is a pivotal moment for investors.

Kura Oncology's new AML drug, KOMZIFTI, sees rapid market uptake, strong financials, and an ambitious plan to reshape targeted cancer therapy.

Biotech firm Immunis, Inc. secures a promising drug candidate to treat a debilitating side effect of Parkinson's therapy, offering hope to millions.

Houston's largest credit union wins its second Gallup award in three years. We explore the strategy connecting happy employees to a thriving bottom line.